National HIV CurriculumLogo
Common TitleARTISTRY-2
Official Title Phase 3 Double-blind Multicenter Randomized Active-Controlled Study to Evaluate the Safety and Efficacy of Bictegravir/Lenacapavir Versus Biktarvy® (Bictegravir/Emtricitabine/Tenofovir Alafenamide) in Virologically Suppressed People With HIV-1
Phase Phase III
ClinicalTrials.gov NCT06333808
Treatments
Bictegravir-Lenacapavir

Bictegravir-Lenacapavir

Tradename:BixlenvoClass:Single-Tablet Regimens
Funding
IndustryGilead Sciences
TagsTwo-drug regimen

Share by e-mail

The Health Resources and Services Administration (HRSA), Department of Health and Human Services (HHS) provided financial support for this website. The award provided 100% of total costs and totaled $1,172,990. The contents are those of the author. They may not reflect the policies of HRSA, HHS, or the U.S. Government.

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.